rss
Br J Ophthalmol 2009;93:387-390 doi:10.1136/bjo.2008.140020
  • Clinical science
    • Original Article

Graft rejection episodes after Descemet stripping with endothelial keratoplasty: part one: clinical signs and symptoms

  1. C S Jordan1,
  2. M O Price2,
  3. R Trespalacios3,
  4. F W Price, Jr4
  1. 1
    Northeastern Eye Institute, Scranton, Pennsylvania, USA
  2. 2
    Cornea Research Foundation of America, Indianapolis, Indiana, USA
  3. 3
    Brevard Eye Center, Melbourne, Florida, USA
  4. 4
    Price Vision Group, Indianapolis, Indiana, USA
  1. Dr M O Price, Cornea Research Foundation of America, 9002 N. Meridian Street, Ste. 212, Indianapolis, IN 46260, USA; mprice{at}cornea.org
  • Accepted 21 October 2008
  • Published Online First 19 November 2008

Abstract

Aim: To investigate characteristics of initial immunological graft rejection after Descemet stripping with endothelial keratoplasty (DSEK).

Methods: The incidence, symptoms and clinical characteristics of initial immunological graft rejection episodes were analysed retrospectively in 598 eyes treated with primary DSEK at a single tertiary referral centre.

Results: Graft rejection episodes occurred in 54 eyes of 48 patients. Thirty-five per cent of the eyes were asymptomatic and were diagnosed during routine examination. Signs of immunological rejection at the initial diagnosis included keratic precipitates (69%), diffuse corneal oedema (11%) or both (20%); no endothelial rejection lines were observed. In contrast to standard full-thickness grafts, there were no epithelial immunological reactions because the epithelium and anterior stroma are not transplanted in DSEK. Most grafts cleared; four (7%) progressed to graft failure and were successfully regrafted with DSEK.

Conclusions: Immunological graft rejection is an important postoperative complication after DSEK. The range of clinical findings indicative of corneal graft rejection differs in some respects between DSEK and standard penetrating keratoplasty.

Footnotes

  • Competing interests: FWP receives travel grants from Moria (Antony, France) and is a consultant for Allergan (Irvine, California).

  • Ethics approval: Ethics approval was provided by IRB Company, Buena Park, California.

  • Patient consent: Obtained.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2008.140020v1
    2. 93/3/387 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.